Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
87.01 EUR | +2.09% |
|
+1.79% | +23.02% |
06-20 | Edwards Lifesciences Insider Sold Shares Worth $492,258, According to a Recent SEC Filing | MT |
06-17 | Edwards Lifesciences Corporation Announces Executive Changes | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analyst opinion has improved significantly over the past four months.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 34.96 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+23.02% | 56.25B | - | ||
+4.18% | 210B | B | ||
+8.00% | 186B | B- | ||
+31.86% | 158B | B- | ||
+33.21% | 113B | A- | ||
+2.28% | 66.13B | A- | ||
+0.11% | 49B | B+ | ||
-6.76% | 38.16B | A | ||
+0.78% | 35.98B | - | ||
+11.28% | 28.14B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- EW Stock
- EWL Stock
- Ratings Edwards Lifesciences Corporation